Prevail Therapeutics Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

organization

SEC Insider

$819.7M

78 transactions

Summary

Prevail Therapeutics Inc. is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $816.4MSales: —18 insiders

Date	Insider	Type	Value
2021-01-22	Joint reporting: ELI LILLY & Co; Tyto Acquisition Corp	Buy	$771.4M
2021-01-22	Thompson Peter A.	D	$0
2021-01-22	Thompson Peter A.	U	—
2021-01-22	GORDON CARL L	D	$0
2021-01-22	GORDON CARL L	U	—
2021-01-22	Nussbaum Ran	D	$0
2021-01-22	Nussbaum Ran	U	—
2021-01-22	Sheng Morgan	D	$0
2021-01-22	Sheng Morgan	D	$0
2021-01-22	Sevigny Jeffrey(Chief Medical Officer)	D	$0
2021-01-22	Sevigny Jeffrey(Chief Medical Officer)	D	$0
2021-01-22	Sevigny Jeffrey(Chief Medical Officer)	D	$0
2021-01-22	Schwartz Kira M.(General Counsel)	D	$0
2021-01-22	Nader Francois	D	$0
2021-01-22	Nader Francois	D	$0
2021-01-22	Nader Francois	D	$0
2021-01-22	Nader Francois	U	—
2021-01-22	Minkow Emily(Chief Business Officer)	D	$0
2021-01-22	Minkow Emily(Chief Business Officer)	D	$0
2021-01-22	Minkow Emily(Chief Business Officer)	D	$0

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

Prevail Therapeutics Inc. — Contributions, Lobbying & Contracts | Poliscope